<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04589546</url>
  </required_header>
  <id_info>
    <org_study_id>PI2020_843_0027</org_study_id>
    <nct_id>NCT04589546</nct_id>
  </id_info>
  <brief_title>Does High-dose Vitamin B3 Supplementation Prevent Major Adverse Kidney Events During Septic Shock?</brief_title>
  <acronym>VITAKI</acronym>
  <official_title>Does High-dose Vitamin B3 Supplementation Prevent Major Adverse Kidney Events During Septic Shock? A Multicenter Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier de Dieppe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier d'Abbeville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Laon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Cherbourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Roubaix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Bethune</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Saint Philibert, Lomme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tourcoing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Valenciennes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Arras</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Lens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Calais</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is the most common cause of acute kidney injury (AKI) in critically ill patients and&#xD;
      is associated with a high mortality rate. Currently there is no available specific treatment&#xD;
      to prevent or treat AKI in this setting. Many experimental and clinical data suggest that&#xD;
      Nicotinamide, a safe and inexpensive vitamin, could be effective to prevent major adverse&#xD;
      kidney events during septic shock. The main objective of the study is to show the superiority&#xD;
      of Nicotinamide supplementation compared to the placebo group, in patients with septic shock&#xD;
      admitted to intensive care. A 15% reduction in the incidence of major renal adverse events at&#xD;
      day 30 is expected in the &quot;Nicotinamide&quot; group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients meeting one or more criteria for MAKE30</measure>
    <time_frame>3 years after study start</time_frame>
    <description>MAKE30 is : in-hospital mortality, receipt of new RRT, or persistent renal dysfunction defined as a final inpatient serum creatinine value ≥2 time baseline serum creatinine</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Septic Shock</condition>
  <condition>Nicotinamide</condition>
  <condition>Mortality</condition>
  <arm_group>
    <arm_group_label>Vitamin B3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinamide treatment</intervention_name>
    <description>Nicotinamide (500 mg) will be mixed in 50 ml of 0.9% saline and administered intravenously every 12 h for a total of 72 h.</description>
    <arm_group_label>Vitamin B3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo treatment</intervention_name>
    <description>For the placebo group, an identical volume of 0.9% saline will be administered in the same manner.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with septic shock defined as sepsis with persisting hypotension&#xD;
             requiring vasopressors to maintain MAP ≥65 mm Hg and having a serum lactate level &gt;2&#xD;
             mmol/L (18 mg/dL) despite adequate volume resuscitation.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of inclusion criteria for more than 24 hours&#xD;
&#xD;
          -  Immediate indication to start renal replacement therapy at the time of randomization:&#xD;
             Hyperkalemia≥ 6.5 mmol /l, metabolic acidosis with pH &lt;7.15 not controlled by medical&#xD;
             treatment, diuretic resistant acute pulmonary edema or accumulation of a toxic&#xD;
             requiring dialysis.&#xD;
&#xD;
          -  Formal indication of Nicotinamide supplementation according to the attending physician&#xD;
             (eg pellagra, undernutrition, severe alcoholism)&#xD;
&#xD;
          -  Known severe chronic kidney disease (clearance &lt;30 ml /min) in the last 3 months&#xD;
             preceding the setic shock or kidney transplant recipient.&#xD;
&#xD;
          -  Moribund patient (estimated survival less than 24 hours)&#xD;
&#xD;
          -  Patient who are not expected to survive to day 30 due to terminal-stage disease&#xD;
             (terminal respiratory or heart failure, Child C cirrhosis, uncontrolled cancer)&#xD;
&#xD;
          -  Resuscitated cardiac arrest&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Legal tutorship and guardianship&#xD;
&#xD;
          -  Lack of social security coverage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dimitri Titeca-Beauport, MD</last_name>
    <phone>0322456411</phone>
    <email>dimitri.titeca@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri Titeca-Beauport, MD</last_name>
      <phone>0322456411</phone>
      <email>dimitri.titeca@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Louis DECLERCQ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hervé DUPONT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine RIVIERE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eloi GOULLIEUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien DUCHEYRON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand SAUNEUF, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven GRANGE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick HERBECQ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe VINSONNEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry VAN DER LINDEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier LEROY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maxime GRANIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier THEVENIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Bayekula, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien Maizel, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabien LAMBIOTTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Kidney Injury</keyword>
  <keyword>Septic Shock</keyword>
  <keyword>Nicotinamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

